10,516 results match your criteria Leukemia Cutis

Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations.

J Hematol Oncol 2022 May 13;15(1):60. Epub 2022 May 13.

Department of Internal Medicine, Hematology and Oncology, Masaryk University Hospital, Brno, Czech Republic.

Background: Extramedullary manifestations (EM) are rare in acute myeloid leukemia (AML) and their impact on clinical outcomes is controversially discussed.

Methods: We retrospectively analyzed a large multi-center cohort of 1583 newly diagnosed AML patients, of whom 225 (14.21%) had EM. Read More

View Article and Full-Text PDF

Identification of Diagnostic Gene Markers and Immune Infiltration in Systemic Lupus.

Comput Math Methods Med 2022 10;2022:3386999. Epub 2022 May 10.

Department of Rheumatology and Immunology, Southwest Medical University, Sichuan Province 646000, China.

Background: Systemic lupus erythematosus (SLE) is an autoimmune disease involving multiple organs, with atypical clinical manifestations and indefinite diagnosis and treatment. So far, the etiology of the disease is not completely clear. Current studies have known the interaction of genetic system, endocrine system, infection, environment, and other factors. Read More

View Article and Full-Text PDF

Mast cell neoplasm: a challenging pathological diagnosis.

Hum Pathol 2022 May 9. Epub 2022 May 9.

Instituto D'Or de Pesquisa e Ensino (IDOR), São Paulo, Brazil; Laboratory of Investigative Pathology, CIPED, University of Campinas (Unicamp), Campinas, São Paulo, Brazil; Anatomic Pathology D'Or Hospitals Network, São Paulo, Brazil; Multipat Laboratory of Pathology, Campinas, São Paulo, Brazil.

Systemic mastocytosis (SM) is a myeloid neoplasm characterized by abnormal growth and accumulation of neoplastic mast cells in at least one extracutaneous site. Clinical presentation and course are variable, most patients developing an indolent disease and some, an aggressive/leukemic form. Because of its rarity, most physicians are unfamiliar with this disease and do not readily diagnose it. Read More

View Article and Full-Text PDF

A case of pseudomyogenic hemangioendothelioma misdiagnosed as low-grade malignant fibrous histiocytoma and review of literature.

Zhong Nan Da Xue Xue Bao Yi Xue Ban 2022 Mar;47(3):390-395

Department of Pathology, Xiangya Hospital, Central South University, Changsha 410008, China.

Pseudomyogenic hemangioendothelioma (PHE) is a rare angiogenic tumor. Histologically, the morphological characteristics of neoplastic vessels and endothelial differentiation are not obvious, and it is easy to be confused with epithelioid sarcoma, epithelioid hemangioendothelioma and myogenic tumor. PHE usually occurs in arms and legs in young people and has a significant male predominance. Read More

View Article and Full-Text PDF

Long-Term Follow-Up of Multiple Myeloma Patients Treated with Tandem Autologous Transplantation Following Melphalan and Upon Recovery, Total Marrow Irradiation.

Transplant Cell Ther 2022 May 6. Epub 2022 May 6.

Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA. Electronic address:

Background: Total body irradiation in combination with melphalan for multiple myeloma (MM), was shown to be prohibitively toxic. To ameliorate toxicity, total marrow irradiation (TMI), was given as the sole ablative modality during the second cycle of tandem autologous stem cell transplant (TASCT) for MM patients on a phase I-II trial.

Study Design: Patients with MM in response or with stable disease and ≤ 18 months from diagnosis received melphalan (MEL) 200 mg/m and ASCT (Cycle 1), and, after recovery, TMI and ASCT (Cycle 2) followed by maintenance with an IMiD and dexamethasone for up to 12 months. Read More

View Article and Full-Text PDF

Blastic Plasmacytoid Dendritic Cell Neoplasm With Central Nervous System Involvement: A Case Report.

Cureus 2022 Apr 6;14(4):e23888. Epub 2022 Apr 6.

Hematopathology, Synlab, Medellín, COL.

Blastic plasmacytoid dendritic cell neoplasm is a rare hematologic neoplasm characterized by cutaneous, hematologic, and central nervous system (CNS) involvement with poor prognosis. Diagnosis is made by flow cytometry, although there are no specific markers, making its diagnosis challenging. So far, with the available evidence, acute lymphoid leukemia-type schemes and consolidation with allogeneic transplant seem to become the first-line therapy. Read More

View Article and Full-Text PDF

Leukemia Cutis Mimicking Granulomatous Rosacea at the Onset of Chronic Lymphocytic Leukemia.

Actas Dermosifiliogr 2022 03 26;113(3):326-328. Epub 2021 Jul 26.

Servicio de Dermatología, Hospital Universitario de Cabueñes, Gijón, Asturias, España.

View Article and Full-Text PDF

Leukemia cutis with chronic myelomonocytic leukemia presenting with a variety of skin lesions.

J Dtsch Dermatol Ges 2022 May 8. Epub 2022 May 8.

Department of Dermatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Yushima, Bunkyo-ku, Tokyo, Japan.

View Article and Full-Text PDF

[Translated article] Leukemia Cutis Mimicking Granulomatous Rosacea at the Onset of Chronic Lymphocytic Leukemia.

Actas Dermosifiliogr 2022 03 11;113(3):T326-T328. Epub 2022 Feb 11.

Servicio de Dermatología, Hospital Universitario de Cabueñes, Gijón, Asturias, Spain.

View Article and Full-Text PDF

Indispensable role of immunophenotyping in diagnosing leukemic phase of blastic plasmacytoid dendritic cell neoplasm without cutaneous manifestation.

Leuk Res Rep 2022 25;17:100317. Epub 2022 Apr 25.

Section of Hematology & Transfusion Medicine, Department of Pathology and Laboratory Medicine, Aga Khan University Hospital, Karachi, Pakistan.

Blastic plasmacytoid dendritic cell neoplasm usually presents as skin lesions. Diagnostic error occurs when it primarily presents in leukemic phase without skin involvement. Triad of CD4, CD56 and CD123 immunophenotype expression is essential to avoid misdiagnosis of this rare hematological malignancy. Read More

View Article and Full-Text PDF

Hypercalcemia as the Initial Presentation of Acute T-cell Leukemia/Lymphoma.

Cureus 2022 Mar 31;14(3):e23705. Epub 2022 Mar 31.

Department of Dermatology, New York University, New York, USA.

Adult T-cell leukemia/lymphoma (ATLL) is a T-cell malignancy that generally presents with widespread involvement of lymph nodes, peripheral blood, and/or skin. It is an uncommon malignancy linked to the human T-lymphotropic virus 1 (HTLV-1). Herein, we present a case of ATLL that was diagnosed after a patient presented to our hospital with nonspecific symptoms of fatigue and weakness and was subsequently found to have hypercalcemia secondary to his blood malignancy. Read More

View Article and Full-Text PDF

A comprehensive model to predict severe acute graft-versus-host disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation.

Exp Hematol Oncol 2022 May 3;11(1):25. Epub 2022 May 3.

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, China.

Background: Acute graft-versus-host disease (aGVHD) remains the major cause of early mortality after haploidentical related donor (HID) hematopoietic stem cell transplantation (HSCT). We aimed to establish a comprehensive model which could predict severe aGVHD after HID HSCT.

Methods: Consecutive 470 acute leukemia patients receiving HID HSCT according to the protocol registered at https://clinicaltrials. Read More

View Article and Full-Text PDF

Erythema nodosum after azacitidine in a patient with acute myeloid leukemia.

J Oncol Pharm Pract 2022 May 3:10781552221098422. Epub 2022 May 3.

Division of Hematology, Oncology, and Transplantation, Department of Medicine, 5635University of Minnesota, Minneapolis, MN, USA.

Introduction: Nodular skin lesions in patients with acute myeloid leukemia (AML) raise clinical suspicion for leukemia cutis versus fungal infections. Here, we report a rare case of treatment-related erythema nodosum (EN) in a patient with AML.

Case Report: Approximately 5 weeks after the initiation of sorafenib and one week after azacitidine initiation, a 32-year-old man with primary refractory AML presented with several painful red nodules on the lower extremities. Read More

View Article and Full-Text PDF

Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells.

Nat Commun 2022 Apr 28;13(1):2228. Epub 2022 Apr 28.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with poor outcomes with conventional therapy. Nearly 100% of BPDCNs overexpress interleukin 3 receptor subunit alpha (CD123). Given that CD123 is differentially expressed on the surface of BPDCN cells, it has emerged as an attractive therapeutic target. Read More

View Article and Full-Text PDF

Development of a Novel Anti-Mouse CCR4 Monoclonal Antibody (CMab-1) by N-Terminal Peptide Immunization.

Monoclon Antib Immunodiagn Immunother 2022 Apr;41(2):87-93

Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.

The CC chemokine receptor type-4 (CCR4) belongs to the G-protein-coupled receptor superfamily, expressed on the cell surface of T cells and its malignancy. Two CCR4 ligands (CCL17 and CCL22) bind to CCR4 that mediate physiological and pathological functions of T cell immune responses. Anti-CCR4 monoclonal antibody (mAb) mogamulizumab is approved for adult T cell leukemia/lymphoma and cutaneous T cell lymphomas. Read More

View Article and Full-Text PDF

Clinical Profile and Treatment in Hypereosinophilic Syndrome Variants: A Pragmatic Review.

J Allergy Clin Immunol Pract 2022 Apr 22. Epub 2022 Apr 22.

Epidemiology, Value Evidence and Outcomes, Global R&D, GSK, Collegeville, PA, USA.

Background: Hypereosinophilic syndrome (HES) is a group of rare hematologic disorders leading to eosinophil-driven tissue damage and dysfunction. Better understanding of HES variants may facilitate improved patient management.

Objective: To describe disease characteristics, treatment and outcomes of patients with idiopathic (I-HES), myeloproliferative (M-HES), lymphocytic (L-HES) and chronic eosinophilic leukemia, not otherwise specified (CEL-NOS) among HES case reports and aggregate data where available. Read More

View Article and Full-Text PDF

Extramedullary Acute Leukemia-Still an Unforeseen Presentation.

Hematol Rep 2022 Apr 18;14(2):143-148. Epub 2022 Apr 18.

Divino Espírito Santo's Hospital, 9500-370 Ponta Delgada, Portugal.

Myeloid sarcomas (MS) are rare extramedullary (EM) hematological tumors that generally arise during the natural course of acute myeloid leukemia (AML), occurring concomitantly with the onset of systemic leukemia; it can also occur following onset but rarely before. Common sites of EM involvement include the lymph nodes, skin, soft tissue, bone and peritoneum. Herein, we report the case of a 63-year-old man who presented EM AML upon initial diagnosis involving the bone marrow, lymph nodes and skin (leukemia cutis). Read More

View Article and Full-Text PDF

Rosacea Granulomatosis in a Neutropenic Leukemic Patient.

Cureus 2022 Mar 19;14(3):e23308. Epub 2022 Mar 19.

Infectious Disease, H. Lee Moffitt Cancer Center, Tampa, USA.

Rosacea granulomatosis is a common, chronic skin disorder that primarily affects the central face, namely the cheek, nose, chin, and central forehead. Although rosacea is mainly a disorder of innate and adaptive immunity, a variety of endogenous and exogenous triggers such as may stimulate it. Often found as commensal organisms in human skin, ​​​​​​​can be parasitic if there is a change in the host's cutaneous environment. Read More

View Article and Full-Text PDF

Deconvolution of Adult T-Cell Leukemia/Lymphoma With Single-Cell RNA-Seq Using Frozen Archived Skin Tissue Reveals New Subset of Cancer-Associated Fibroblast.

Front Immunol 2022 7;13:856363. Epub 2022 Apr 7.

Genome Medicine Institute, Seoul National University College of Medicine, Seoul, South Korea.

Adult T-cell Leukemia/Lymphoma (ATLL) is a rare aggressive T-cell malignancy caused by human T-cell leukemia virus type 1 (HTLV-1) infection. However, little is known about the underlying activated molecular pathways at the single cell level. Moreover, the intercellular communications between the tumor microenvironment (TME) and tumor cells in this malignancy are currently unknown. Read More

View Article and Full-Text PDF

Identification of a Cancer-Predisposing Germline p.Ile49Metfs*7 Variant by Targeted Sequencing of a Splenic Marginal Zone Lymphoma.

Genes (Basel) 2022 03 26;13(4). Epub 2022 Mar 26.

Department of Pathology and Laboratory Medicine, University Hospitals Cleveland Medical Center, 11100 Euclid Avenue, Cleveland, OH 44106, USA.

Germline disruptive variants in () predispose to a wide variety of cancers, including melanoma, chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, myeloproliferative neoplasms, and glioma. We report the first case of splenic marginal zone lymphoma (SMZL) arising in a patient with a germline variant: a 65-year-old male with an extensive history of cancer, including melanoma and papillary thyroid carcinoma, who presented with circulating atypical lymphocytosis. Bone marrow biopsy revealed 20% involvement by a CD5CD10 B-cell lymphoma that was difficult to classify. Read More

View Article and Full-Text PDF

Bosutinib-Induced Stevens-Johnson Syndrome and Evidence of Tolerance to a Structurally Dissimilar Tyrosine Kinase Inhibitor.

Cureus 2022 Mar 18;14(3):e23288. Epub 2022 Mar 18.

Division of Pulmonary, Allergy, and Sleep Medicine, Department of Medicine, Mayo Clinic, Jacksonville, USA.

Bosutinib is a breakpoint cluster region-Abelson gene (BCR-ABL) tyrosine kinase inhibitor (TKI) used for the treatment of chronic myeloid leukemia (CML). Patients on TKIs may develop severe cutaneous adverse reactions (SCARs). A 73-year-old female with CML treated with a second-generation TKI (bosutinib) was evaluated after developing fever and a maculopapular exanthema with skin-peeling affecting her lips, oral mucosa, and genitals 10 days after starting the medication. Read More

View Article and Full-Text PDF

Invasive Fusariosis in Pediatric Hematology/Oncology and Stem Cell Transplant Patients: A Report from the Israeli Society of Pediatric Hematology-Oncology.

J Fungi (Basel) 2022 Apr 11;8(4). Epub 2022 Apr 11.

Department of Pediatric Hemato-Oncology, Sourasky Medical Center, Tel Aviv 6423906, Israel.

Invasive species infections in immunocompromised patients occur predominantly in those with hematological malignancies. Survival rates of 20-40% were reported in adults, but data in children are limited. Our retrospective, nationwide multicenter study of invasive fusariosis in pediatric hematology/oncology and stem cell transplant (SCT) patients identified twenty-two cases. Read More

View Article and Full-Text PDF

Skin and soft tissue infections in adolescent chronic myeloid leukemia under dasatinib treatment.

Pediatr Blood Cancer 2022 Apr 20:e29714. Epub 2022 Apr 20.

Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.

Although skin complications are common adverse events from tyrosine kinase inhibitors (TKIs) for the treatment of chronic myeloid leukemia (CML), no reports have focused on skin and soft tissue infections (SSTIs) associated with TKI use. We herein present five episodes of SSTIs in three CML patients under dasatinib treatment. All patients were adolescents and had been receiving dasatinib for more than 4 years. Read More

View Article and Full-Text PDF

Feasibility and limitations of cultured skin fibroblasts for germline genetic testing in hematologic disorders.

Hum Mutat 2022 Apr 14. Epub 2022 Apr 14.

Section of Hematology/Oncology and Center for Clinical Cancer Genetics, University of Chicago, Chicago, Illinois, USA.

To avoid acquired variants found in the blood, cultured skin fibroblasts are a recommended DNA source for germline genetic testing in patients with hematologic disorders, but data are lacking regarding practicality and limitations. We conducted a retrospective cohort study of 350 subjects with hematologic disorders who underwent skin fibroblast culture for germline genetic testing. We analyzed next-generation sequencing data from the targeted capture of 144 inherited cancer and bonemarrow failure genes to identify variants at heterozygous and subclonal variant allele frequencies. Read More

View Article and Full-Text PDF

Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.

Cancer 2022 Apr 13. Epub 2022 Apr 13.

Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.

Background: Ruxolitinib is approved for patients with polycythemia vera (PV) who are resistant/intolerant to hydroxyurea, but its impact on preventing thrombosis or disease-progression is unknown.

Methods: A retrospective, real-world analysis was performed on the outcomes of 377 patients with resistance/intolerance to hydroxyurea from the Spanish Registry of Polycythemia Vera according to subsequent treatment with ruxolitinib (n = 105) or the best available therapy (BAT; n = 272). Survival probabilities and rates of thrombosis, hemorrhage, acute myeloid leukemia, myelofibrosis, and second primary cancers were calculated according to treatment. Read More

View Article and Full-Text PDF

Necrotizing fasciitis of the vulva due to carbapenem-resistant Enterobacteriaceae as a complication of acute myeloid leukemia treatment: a case report.

J Med Case Rep 2022 Apr 11;16(1):148. Epub 2022 Apr 11.

Department of Hematology and Bone Marrow Transplantation, Centro Hospitalar Universitário de Lisboa Norte, Lisbon, Portugal.

Background: Carbapenem-resistant Enterobacteriaceae strains have been reported in healthcare facilities with a rising incidence and are a major concern owing to infections that are often severe and can be potentially fatal, with limited therapeutic options. Klebsiella pneumonia represents the most frequently isolated microorganism.

Case Presentation: We report the case of a Caucasian 52-year old Caucasian woman with acute myeloid leukemia was admitted to the inpatient hematology unit at a university referral hospital in Portugal. Read More

View Article and Full-Text PDF

A Case of Indeterminate Cutaneous Dendritic Cell Tumors in the Setting of Chronic Myelomonocytic Leukemia.

Am J Dermatopathol 2022 Apr 6. Epub 2022 Apr 6.

Kansas City University Graduate Medical Education Consortium, Orlando Dermatology Residency, Advanced Dermatology and Cosmetic Surgery, Orlando, FL.

Abstract: Chronic myelomonocytic leukemia (CMML) is a rare hematopoietic stem cell neoplasm. Indeterminate dendritic cell neoplasm (IDCN) is an extraordinarily rare histiocytosis that may manifest secondarily to CMML. A 75-year-old man with a 2-year history of CMML presented for multiple cutaneous lesions on his head and neck. Read More

View Article and Full-Text PDF

Erythroderma: An unusual manifestation of imatinib - A rare case report.

J Cancer Res Ther 2022 Jan-Mar;18(1):253-256

Department of Medical Oncology and Hematology, GCRI, Ahmedabad, Gujarat, India.

Imatinib is a tyrosine kinase inhibitor that selectively inhibits several protein tyrosine kinases which is central to the pathogenesis of human cancer. It forms the first-line treatment for chronic myeloid leukemia (CML) and gastrointestinal stromal tumors. Usually, the drug is well-tolerated with relatively few side effects. Read More

View Article and Full-Text PDF

Mouse models of graft-versus-host disease.

Methods Cell Biol 2022 17;168:41-66. Epub 2022 Jan 17.

Bone Marrow Transplantation & Leukemia, Oncology Division, Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO, United States.

Transplantation of allogeneic hematopoietic stem and progenitor cells (allo-HCT) allows for cure of life-limiting malignant and non-malignant hematologic diseases. Crossing the human leukocyte antigen (HLA) barrier, however, comes at the cost of graft-versus-host disease (GVHD), a life-threatening syndrome mediated in part by the same donor T-lymphocytes that eliminate malignant cells. Acute GVHD occurs in the skin, gut, and/or liver in 25-55% of patients with a mortality rate of 15-40%, while chronic GVHD develops in 30-65% of patients who survive at least 3 months following allo-HCT and is highly debilitating in its extensive form, with a 30-50% 5year mortality rate stemming in part from immune dysregulation and opportunistic infections. Read More

View Article and Full-Text PDF

Total-Body Irradiation Is Associated With Increased Incidence of Mesenchymal Neoplasia in a Radiation Late Effects Cohort of Rhesus Macaques (Macaca mulatta).

Int J Radiat Oncol Biol Phys 2022 Mar 28. Epub 2022 Mar 28.

Department of Pathology, Section on Comparative Medicine; Department of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, North Carolina. Electronic address:

Purpose: Cancer is a severe delayed effect of acute radiation exposure. Total-body irradiation has been associated with an increased risk of solid cancer and leukemia in Japanese atomic bomb survivors, and secondary malignancies, such as sarcoma, are a serious consequence of cancer radiation therapy. The radiation late effects cohort (RLEC) of rhesus macaques (Macaca mulatta) is a unique resource of more than 200 animals for studying the long-term consequences of total-body irradiation in an animal model that closely resembles humans at the genetic and physiologic levels. Read More

View Article and Full-Text PDF